Organic Active Ingredients TRIZ Cases

Using asenapine acid addition salt with a desalting agent in an acrylic adhesive patch reduces degradation during manufacturing while preserving efficacy.

Targeting TA-MUC1 with an antibody-drug conjugate delivers exatecan into resistant cancer cells, extending options beyond existing ADCs.

Bicyclic amines selectively inhibit CDK2 to treat cancers with deregulated CDK2 activity and help address resistance in CCNE1-driven tumors.

Chemically modified AAV capsids add cell-specific ligands to improve transduction while reducing liver off-targeting, toxicity, and dose needs.

SBEβCD inclusion complexation with bicarbonate raises meloxicam solubility and absorption, supporting rapid and sustained pain relief.

CMP conjugates target therapeutic compounds to diseased tissue, reducing systemic side effects, dosage needs, and supporting faster healing.

Phytoecdysones restore the ACE2/Ang-1-7/MasR pathway to treat viral respiratory impairment while avoiding hypotensive effects.

Solid PVA-based microspheres carry chemotherapy drugs and iodine-131 for lasting embolization, slow release, and real-time tumor imaging.

A crystalline salt form of a plasma kallikrein inhibitor improves oral formulation while helping prevent thrombus reocclusion and bleeding.

A multi-arm CD44-targeted conjugate improves tumor-specific drug concentration while reducing normal-cell toxicity in high-CD44 cancers.

Olive leaf extract with oleuropein and oleuroside activates HIF-1 to support stem cell state control and improve hematopoiesis and vascular function.

Guanidinium-functionalized polylysine uses electrostatic attraction to target pathogens and cancer cells while broadening activity and reducing resistance.

Immunosuppressants such as tacrolimus or dexamethasone reduce xenogeneic immune rejection and improve mesenchymal stem cell survival.

Selective triazolone antagonists target A2aR and A2bR while preserving solubility and limiting CB-1 off-target binding to enhance antitumor immunity.

Carboxylic acid azetidinyl compounds target S1P5 to support myelin formation and slow neurodegenerative disease progression.

Crystalline salt forms of a CFTR modulator improve stability and purity while preserving dissolution needed to enhance anion transport in cystic fibrosis.

Small-molecule PCSK9 inhibitors replace injectable antibodies with oral compounds that lower LDL cholesterol and support sepsis treatment.

A pH-dependent gamma-hydroxybutyrate formulation splits release across acidic and neutral media to match twice-nightly exposure in one dose.

Novel selenoxoimidazolidine compounds inhibit NOX, limit α-synuclein aggregation, and protect dopaminergic neurons from ROS-driven death.

A nonionic dexketoprofen-lidocaine associated form enables sustained transdermal release without permeation enhancers, reducing irritation.

By targeting conserved Cra4S1 and outer membrane antigens, this vaccine improves stable protection against P. gingivalis strains.

Buffered pH 6-8 clonidine oral liquid uses phosphate salts and propylene glycol to improve stability, taste, and ready-to-use dosing.

Mucin-derived glycopeptides help infant formula promote Bifidobacterium and Lactobacillus while limiting pathogenic gut bacteria.

N4-hydroxycytidine derivatives and aerosol formulations help prevent or treat alphavirus and flavivirus infections by lowering viral load.

A pine bark, berry extract, and L-theanine blend improves mental clarity without caffeine jitteriness or unwanted ingredient interactions.

A bioerodible ocular insert delivers vorolanib locally with sustained release for up to 270 days while minimizing systemic toxicity and repeat dosing.

Formula (I) ASK-1 inhibitor compounds balance broad therapeutic use across liver, inflammatory, and neurodegenerative diseases with manageable development complexity.

PEGylated stealth liposomes improve MRSA antibiotic delivery by boosting infection-site accumulation, biofilm penetration, and kidney safety.

Substituted imidazolecarboxamide compounds inhibit BTK to extend treatment beyond cancer into autoimmune, inflammatory, and allergy indications.

Targeted lipid nanoparticles deliver CAR or TCR nucleic acids into T cells, cutting viral vector cost, production time, and antigenicity.

Allosteric M4 modulators improve receptor selectivity beyond the conserved orthosteric site, aiming to reduce peripheral cholinergic side effects.

High-pressure homogenized phospholipid micelles improve pregabalin skin absorption, extending topical neuropathic pain relief beyond five hours.

Combining PARP inhibitors with deoxyuridine analogs drives selective DNA damage in p53-deficient cancers while sparing wild-type cells.

Multiple crystalline, amorphous, and solvated FGFR inhibitor forms improve handling, stability, dissolution, and bioavailability for cancer therapy.

Novel neuroactive steroid compounds modulate GABAA receptors to treat CNS disorders while addressing side effects seen with older therapies.

Local sex steroid release at a repaired enthesis promotes healing genes, lowers re-tear risk, and avoids systemic hormone exposure.

Novel pharmacological chaperones enhance glucocerebrosidase activity to limit protein aggregation and treat Gaucher's and CNS degenerative disorders.

Crystalline Form A of leflutrozole enables high-purity dosing that raises testosterone and lowers estradiol without daily application.

Oral trigonelline raises intracellular NAD+ through metabolic conversion, supporting mitochondrial function in aging, metabolic, and neurodegenerative states.

An oral benzothiazole aniline composition shrinks liver tumors while reducing the toxicity seen with cisplatin treatment.

A quinoline IDO inhibitor is paired with HDAC modulation to improve immune regulation and treatment potential in tryptophan metabolism disorders.

Ulipristal-based dengue therapy blocks viral entry into host cells and pairs with GOViRA screening for faster, reproducible antiviral analysis.

Separate chambers keep polymer, cationic compound, and drug stable until mixing, enabling easy nanoparticle formation for drug delivery.

Using the S(−)-cibenzoline enantiomer, this case shows a composition that lowers LVOT gradient and improves symptoms in hypertrophic cardiomyopathy.

A pentaaza macrocyclic ring complex is combined with checkpoint inhibitors to sensitize tumors and strengthen immune response against cancer cells.

Baseline TIMP1, pro-MMP10, and PECAM1 levels guide ivaltinostat maintenance therapy in PDAC to improve survival while limiting toxicity.

Digital monitoring of mood, response, and interaction data helps personalize 5-MeO-DMT benzoate dosing for more reliable treatment outcomes.

Specific KIT inhibitor compounds target mast cells more precisely, reducing healthy-cell side effects while improving treatment of KIT-mediated diseases.

Isolated mitochondria-rich organelle complexes reprogram T cells to improve expansion, persistence, cytotoxicity, and resistance to exhaustion.

A heterologous probiotic blend eases menopause symptoms while supporting bone density through gut microbiome shifts and vitamin K2 biosynthesis.